Floatz logo

ELEXACAFTOR

Chronic Rhinosinusitis

University of California, Los AngelesSmall moleculeUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chronic Rhinosinusitis cohort.

Asset / SponsorPhaseRating
Escitalopram
University of Washington
Phase 4BB
Omalizumab
University of California, San Francisco
Phase 4BB
METHOXIFLURANE
St. Paul's Hospital, Canada
Phase 1/2CCC
Jnj-54135419
The Second People's Hospital of Huai'an
Phase 1/2CC
Ivacaftor
University of California, Los Angeles
UnknownD

View all 9 →

Same molecule, other indications

ELEXACAFTOR is also rated in:

cystic fibrosisActive
BBB
Indicative · Phase 4
76 / 100
View asset →
olfactory nerve disorderActive
D
Indicative · Unknown
30 / 100
View asset →
anosmiaActive
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →